# Primary Cutaneous Cryptococcosis Treated with Debridement and Fluconazole Monotherapy in an Immunosuppressed Patient: A Case Report and Review of the Literature

Authors: Jennifer Wang; Luther Bartelt; Deborah Yu; Anjali Joshi; Bradley Weinbaum; Tiffany Pierson; Michael Patrizio; Cirle A. Warren; Molly A. Hughes; Gerald Donowitz
Journal: Case Reports in Infectious Diseases
 (2015)

---

## Abstract

Cryptococcus neoformans is an opportunistic yeast present in the environment. Practitioners are familiar with the presentation and management of the most common manifestation of cryptococcal infection, meningoencephalitis, in patients with AIDS or other conditions of immunocompromise. There is less awareness, however, of uncommon presentations where experience rather than evidence guides therapy. We report a case of primary cutaneous cryptococcosis (PCC) in a patient who had been immunosuppressed by chronic high-dose corticosteroid for the treatment of severe asthma. This case highlights the importance of early recognition of aggressive cellulitis that fails standard empiric antibiotic treatment in an immunocompromised patient. It also demonstrates successful treatment of PCC with a multispecialty approach including local debridement and fluconazole monotherapy.


---

## Body

## 1. Introduction

Cryptococcus is an encapsulated yeast, classified into four serotypes based on immunologic reactivity of the capsular polysaccharides [1].C. neoformans var.neoformans belongs to serotype D and is the most prevalent serotype in the USA [2]. It is present in the environment and has been isolated from pigeon droppings, decaying wood, fruits, and vegetables [3]. Patients with impaired cell-mediated immunity, such as those infected with HIV, solid-organ transplant recipients, and those on chronic corticosteroid therapy, are most vulnerable to cryptococcal infections [4].Cryptococcus can present with a variety of skin and soft tissue manifestations including acneiform lesions, purpura, vesicles, nodules, abscesses, ulcers, granulomas, pustules, draining sinuses, and cellulitis. Most skin and soft tissue manifestations occur in the setting of disseminated disease, which is apparent in 10–15% of patients with systemic cryptococcosis [5]. Primary cutaneous infection as a result of direct local inoculation, however, is rare.


## 2. Case

A 56-year-old male carpenter with a past medical history of hypertension, uncontrolled diabetes mellitus, and severe asthma had been treated with prolonged courses of oral prednisone up to 100 milligrams (mg) daily for several months and at least 50 mg daily for the past 7 consecutive months. He presented to the emergency department (ED) with a rapidly enlarging plaque on his right forearm. Five days prior to admission, the patient was moving firewood in his backyard when he noticed a pustule on his volar right forearm. The pustule became erythematous and indurated throughout the next day, and the patient presented to a walk-in clinic where clindamycin was prescribed. Despite this therapy, the erythema continued to expand, and the forearm became painful. The patient represented to his primary care doctor who added linezolid to his antibiotic regimen. Of note, the patient was intolerant to penicillin, sulfa drugs, erythromycin, ciprofloxacin, doxycycline, and metronidazole. Despite the change in antibiotic therapy, the erythema continued to expand prompting a visit to the ED (Figure1(a)). He denied fever, night sweats, malaise, or other systemic symptoms. A pustule was noted on exam with minimal fluid expressed. A bedside ultrasound was performed that did not reveal a subcutaneous abscess. The patient was sent home with the instruction to continue clindamycin and linezolid. The patient noticed worsening of his rash with purulent drainage and returned to the ED the next day. He was found to be afebrile with a pulse of 110 beats per minute, a respiratory rate of 20 breaths per minute, and blood pressure of 141/85 mmHg. Physical examination revealed a single 7 cm painful bulla with surrounding erythema that extended proximal to the elbow (Figure 1(b)). Lymphadenopathy was absent. Laboratory testing was significant for a leukocytosis of 17,500 cells/μL (83.6% neutrophils, 1.8% band, and 1.8% atypical lymphocyte) and a hemoglobin A1c of 8.8%.Primary cutaneous cryptococcosis of the right forearm. Progressive skin changes documented at the initial visit to the emergency department on the third day of symptoms (a), during hospitalization (b-c), and at postdischarge clinic follow-up (d). White arrows denote the outlines of the region of erythema marked on each respective day prior to presentation (i.e., Days 1–3). Fluconazole was initiated along with two interrupted doses of amphotericin on Day 3. Broad-spectrum antibacterial therapy with vancomycin and piperacillin-tazobactam (Day 5–Day 7), ampicillin-sulbactam (Day 8–Day 10), and amoxicillin-clavulanate (Day 11–Day 17) was also administered. (e) Wound improvement seen on one-week follow-up in clinic. The gram stain (f) from fluid expressed on Day 5 demonstrated abundant variably sized encapsulated spherical yeast forms (*) that were identified asC. neoformans on blood agar.
(a)
(b)
(c)
(d)
(e)
(f)The antibiotics were changed to vancomycin and piperacillin/tazobactam, and the patient was admitted to the general medicine service. Plastic surgery was consulted. The epidermis of the bulla was carefully removed, draining a copious amount of purulent material with an unusual watery consistency. The expressed fluid gram stain revealed yeast forms and no bacteria (Figure1(f)). Culture of the purulent material grew onlyCryptococcus neoformans. Serological investigation for HIV was negative, and the patient’s risk factor for immunosuppression was identified to be the chronic prednisone use. The patient was subsequently initiated on intravenous liposomal amphotericin B at 3 mg/kg/day for potential disseminated cryptococcal infection. However, he developed severe chest pain during liposomal amphotericin B administration that resolved after termination of the infusion. A second trial of liposomal amphotericin B was also terminated early due to recurrence of chest pain. In total, he received less than 300 mg (one dose) of liposomal amphotericin B. A decision was made to initiate oral fluconazole (12 mg/kg/day), which he tolerated well.Workup for disseminated disease and meningeal involvement including serum cryptococcal antigen, blood culture, urine culture, computed tomography scan of the head, chest, abdomen, and pelvis, and cerebral spinal fluid (CSF) analysis for cryptococcal antigen all returned negative. The fluconazole dose was decreased to 8 mg/kg/day. Serial liver function test and QTc were monitored. In addition to systemic therapy forCryptococcus, daily dressing changes with a Pluronic antimicrobial cream manufactured at our institution (Kolliphor P 188 50%, polymyxin 10,000 units/gram, nystatin 4,000 units/gram, and nitrofurantoin 0.3% within a Pluronic F68 carrier) were performed for topical preemptive antibacterial and antifungal coverage during wound healing. The patient continued to feel well with improvement in his arm tenderness. However, the surrounding erythema persisted with worsening leukocytosis that peaked at 22,000 cells/μL, raising concern for a deeper infection that was not apparent on exam. An MRI of the arm was consistent with the clinical exam of superficial cellulitis with no evidence of abscess or necrotizing fasciitis. Although initial gram stain and cultures were negative, in the context of potential environmental wound contamination while carrying wood and possible inhibition of bacterial culture growth due to concurrent antibacterial therapy, the worsening leukocytosis raised concern for a superimposed bacterial cellulitis in this immunocompromised host, and antibacterial therapy was continued with ampicillin/sulbactam that was later changed to amoxicillin/clavulanate upon discharge.The patient’s wound improved remarkably over the course of his hospital stay with near resolution of the surrounding erythema and edema (Figure1(d)). He was sent home on oral fluconazole 8 mg/kg/day and a total of 14-day course amoxicillin/clavulanate. His prednisone was gradually weaned down to 10 mg/day; however, he had to increase the dosage to 30 mg/day due to asthma exacerbation after 2 months. At a one-week follow-up visit, his wound showed great improvement (Figure 1(e)). Within 3 months of fluconazole therapy, his wound showed complete healing. He tolerated fluconazole well and was continued on an 8 mg/kg/day regimen for an additional 3 months for a total duration of 6 months. He was last seen near completion of his fluconazole therapy (more than 6 months from symptom onset) without signs of relapse (Figure 2). Throughout this time he never experienced evidence of disseminated disease or meningeal involvement, and the serum cryptococcal antigen remained negative at the last clinic visit.Figure 2
Healed right forearm lesion 6 months after symptom onset and at the conclusion of fluconazole therapy. The patient was seen in clinic 6 months after symptom onset and towards the end of the planned 6-month course of fluconazole therapy. Skin pigmentation changes remained, but the ulcer was entirely healed and there was no pain or evidence of subcutaneous involvement. Follow-up clinical evaluation was notable for the absence of systemic symptoms and serial serum cryptococcal antigen remained negative.


## 3. Discussion

Primary cutaneous cryptococcosis (PCC) is defined as identification ofCryptococcus neoformans in a skin lesion without evidence of simultaneous disseminated disease [35]. Most cases of PCC have been reported from Europe, Japan, and South America [6, 7, 9–12, 16–21, 30, 31, 35]. A nationwide survey conducted by the French Cryptococcosis Study Group identified 28 cases of PCC of the 1,974 total cryptococcosis cases reported to the National Reference Center for Mycoses from 1985 to 2000. Of the 28 patients with PCC, 50% were immunocompetent and only 11% had HIV infection, suggesting that PCC can develop regardless of immune status. Five patients were receiving long-term corticosteroid therapy [35]. Neuville et al. also observed that the skin lesions of PCC usually presented as solitary lesions resembling cellulitis, ulceration, or whitlow and were located on unclothed areas. In contrast, lesions from disseminated disease usually presented as scattered umbilicated papules resembling molluscum contagiosum [35]. Although the distinction is nonspecific and should not be used as a diagnostic tool, it is interesting to note that our patient’s presentation is similar to many other patients with PCC. In addition, the French Cryptococcosis Study Group also highlighted that the spectrum of skin manifestations due to either disseminated or primary cutaneous cryptococcosis overlaps with other skin infections, necessitating biopsy for histopathological and microbiological diagnosis [35].The treatment of choice forC. neoformans infection is determined by anatomic site of involvement and the host’s immune status. While recent randomized-control trials are helping to clarify the evidence-based treatment of cryptococcal meningitis in patients with HIV/AIDS [36], management for unusual manifestations of disease in non-HIV-infected populations remains primarily guided by expert opinion. The Infectious Disease Society of America (IDSA) recommendation for patients with noncentral nervous system (CNS), nondisseminatedCryptococcus is oral azole therapy for 6–12 months (B-III recommendation) [37]. Furthermore, it is recommended that non-HIV-infected, nontransplant recipients be treated in the same fashion as those with CNS disease which consists of induction therapy with amphotericin B (or high-dose fluconazole if intolerant to amphotericin) plus flucytosine followed by fluconazole maintenance therapy [37]. Consensus on the duration of induction therapy in this population, however, is lacking as most data come from cohort studies of HIV-infected or organ transplant recipients [38]. The absence of well-controlled randomized trials for PCC or patients on chronic corticosteroids is a limitation in specific treatment guidelines. In most cases, disease remains limited to the skin, but there are reports of secondary systemic dissemination [39], including the CNS, and persistent antigenemia [40]. The patient in our case followed the typical pattern of uncomplicated PCC, manifesting neither systemic symptoms nor a positive serum cryptococcal antigen test.To facilitate management in this case, we performed a literature search in PubMed using the search terms “cutaneous,Cryptococcus, and primary.” After excluding cases of documented or probable disseminated disease, we identified 43 reports in the English language from 1981 through 2014 (Table 1), 23 of which were reported over the last four years, although it is unclear if this is due to a true increase in PCC incidence or increased awareness among physicians, and thus reporting bias. Our search yielded a broad geographic distribution of reported cases among a wide age range in both immunocompetent and immunocompromised hosts. Compared with cases reported in immunocompromised hosts (44.1%), all of which were caused byC. neoformans, immunocompetent hosts had fewer reports of necrotic lesions and more commonly had infection with the emergingC. gattii species (23.3%). Interestingly,C. gattii was reported predominantly in Australia, Singapore, and Brazil, consistent with known restricted geographic distribution ofC. gattii [41]. Other than three deaths, at least two of which were due to other causes, prognosis for PCC in these reports was overwhelmingly favorable as all patients were cured after as few as two weeks (in combination with surgical debridement) to up to ten months of antifungal therapy. In addition, fluconazole monotherapy has been increasingly reported in the recent medical literature, utilized in 17 out of 21 cases since 2011 and 5 out of 22 cases prior to 2011. For cases reported by the French Cryptococcosis Study Group, fluconazole was prescribed to 20 patients regardless of immune status for a median therapy duration of 32 days. Of these patients, 75% were definitively cured and 15% were attenuated [35].Table 1
Clinical characteristics of cases reports of PCC in English language literature searched on PubMed.
Citation
Year
Age/gender
Region of origin
Immune status
Occupation/exposure
Site of lesion
Type of lesion
Species
Medical treatment
Duration of therapy
Topical care
Outcome
[6]
2014
68/male (M)
Southeast Brazil
Immunocompetent
Bus driver
Forearm
Nodule
Cryptococcus gattii
Fluconazole (200 mg/d)
40 days
None documented
Cured
[7]
2013
8/female (F)
Spain (child from Mongolia)
Immunocompetent
Not reported
Forearm
Macule
C. laurentii
Fluconazole (3 mg/kg/d)
2 weeks
None documented
Cured
[8]
2013
87/M
Rural area of Taiwan
Immunocompetent
Not reported
Arm
Indurated papules and plaques
C. neoformans
Fluconazole 400 mg/d for 2 weeks followed by 200 mg/d for 2 weeks
1 month
None documented
Cured
[9]
2012
66/M
Rural Central America
Immunocompetent
Not reported
Penis
Nodule
No fungal culture
Itraconazole (400 mg/d)
3 months
None documented
Cured
[10]
2012
89/M
Brazil
Immunocompetent
Collects firewood
Forearm
Ulceration
C. gattii
Itraconazole (400 mg/d)
3 months
None documented
Cured
[11]
2012
58/M
Greece
Immunocompetent
Poultry farmer
Hand
Ulceration
C. neoformans
Fluconazole (200 mg/d)
2 weeks
Surgical debridement
Cured
[12]
2012
Case series of 11 patients, mean age 71.2/9M2F
Brazil
5 immunocompetent, 6 on corticosteroid therapy
5 reported trauma or exposure to contaminated sources
Forearm
Circumscribed lesions ranged from an infiltrative plaque to a solid tumor mass
3 C. neoformans 4 C. gattii 4 C. spp.
Fluconazole (150 mg/d–400 mg/d)
1–6 months
None documented
9 cured,1 unrelated death,1 marked improvement
[13]
2012
55/M
Not reported
Renal transplant recipient
Not reported
Thigh
Umbilicated
C. laurentii
Amphotericin B + flucytosine
7 days(patient deceased)
None documented
Local lesion improving; however, patient deceased due to other causes
[14]
2011
67/M
Not reported
Immunocompetent
Poultry farmer
Forearm
Nodule
C. neoformans
Fluconazole (450 mg/d)
40 days
None documented
Cured
[15]
2011
37/M
Singapore
Immunocompetent
Forklift driver
Scalp
Nodule
C. gattii
Not reported
[16]
2011
75/M
Brazil
Immunocompetent
HandlesEucalyptuslogs
Forearm
Nodule
C. gattii
Fluconazole
5 months
None documented
Cured
[17]
2010
60/M
Slovenia
Renal transplant recipient
Cat scratch
Hand
Necrosis
C. neoformans
Amphotericin B + fluconazole
3 weeks (amp. + fluc.) + 15 weeks  (fluc.)
Surgical debridement, amputation of the arm
Healed
[18]
2010
58/M
Italy
Immunocompetent
Collects firewood
Hand
Nodule
C. neoformans
Itraconazole (200 mg/d)
4 months
None documented
Cured
[19]
2005
43/M
Saudi Arabia
Immunocompetent
Driver for a furniture company
Forehead
Nodule
C. neoformans
Not reported
[20]
2005
26/M
Japan
Long-term prednisolone therapy for minimal change nephrotic syndrome
Not reported
Leg
Nodule
C. neoformans
Intravenous fluconazole
3 months
None documented
Cured
[21]
2005
73/M
Spain
Liver transplant recipient
Insect bite in Costa Rica 2 days prior to presentation
Arm
Intense edema and suppuration
C. neoformans
Amphotericin B + fluconazole (100 mg/d)
15 days (amp. + fluc.) + 3 months (fluc.)
Surgical debridement and reconstruction
Cured
[22]
2004
57/M
Not reported
Lung transplant recipient
Gardener
Leg
Ulceration
C. neoformans
Fluconazole (200 mg/d)
2 months
None documented
Cured
[23]
2004
81/M
Not reported
Immunocompetent
Cattle farmer
Forearm
Pustules
C. neoformans
Fluconazole (400 mg/d)
2 months
None documented
Cured
[4]
2003
41/M
Southern Wisconsin
Immunocompetent
Puncture wound from hay bale wire in a barn
Hand
Erythematous nodule
C. neoformans
Fluconazole (400 mg/d)
8 weeks
Surgical excision
Cured
[24]
2002
46/M
Not reported
Immunocompetent
Not reported
Finger
Cellulitis
C.  neoformans
Itraconazole (200 mg/d)
10 months
Surgical excision
Cured
[25]
2002
65/M
Brazil
Immunocompetent
Not reported
Forearm
Ulceration
C. gattii
Fluconazole (150 mg/d)
45 days
None documented
Cured
[26]
2000
36/F
Not reported
Liver transplant recipient for Budd-Chiari syndrome
Not reported
Leg
Ulceration
C. neoformans
Fluconazole (200 mg/d)
3 months
None documented
Cured
[27]
1997
75/M
Australia
Immunocompetent
Orchid grower
Forearm
Tender, erythema
C. gattii
Amphotericin B + 5-flucytosine Itraconazole (200 mg/d)
3 weeks3 months
Normal saline and miconazole cream applied once daily
Cured
[28]
1997
77/M
Not reported
Long-term steroid treatment
Chronic obstructive pulmonary disease
Hand
Ulceration
C. neoformans
Amphotericin B + fluconazole
12 days + 6 weeks
None documented
Cured
[29]
1996
62/F
Not reported
Long-term steroid treatment
Sarcoidosis
Forearm
Bullous
C. neoformans
Itraconazole (400 mg/d)
Not reported
None documented
Cured
[30]
1995
73/F
Japan
Immunocompetent
Not reported
Cheeks
Ulceration
C. neoformans
No antifungal therapy
Not reported
Cured
[5]
1992
52/M
Not reported
Renal transplant recipient
Undergoing surgery for below knee amputation
Leg stump
Necrosis
C. neoformans
Amphotericin B
Patient deceased
Surgical debridement
Patient died of multisystem organ failure
[5]
1992
55/M
Not reported
Renal transplant recipient
Polycystic kidney disease
Forearm
Nodule
C. neoformans
Amphotericin B + 5-fluorocytosine
Not reported
None documented
Cured
[5]
1992
27/F
Not reported
Severe lymphopenia
Hereditary lymphangiectasia
Legs, lower abdomen, and groin
Necrosis
C. neoformans
Amphotericin B + 5-fluorocytosine
Not reported
None documented
Cured
[31]
1990
63/F
Japan
Immunocompetent
Housewife
Earlobe
Erosion
C. neoformans
Itraconazole (100 mg/d)
13 weeks
Cured
[32]
1986
7/M
Not reported
Nonspecific failure in cellular immunity
Not reported
Postauricular
Not reported
C. neoformans
No antifungal therapy
Spontaneous healing
[33]
1985
53/M
Not reported
Long-term corticosteroid therapy for asthma
Pigeon fancier
Wrist
Mass
C. neoformans
Ketoconazole
3 months
Cured
[34]
1981
81/M
Not reported
Immunocompetent
Not reported
Forearm
—
—
IV and oral miconazole
25 days
None documented
CuredOur patient had a favorable response to fluconazole monotherapy, amoxicillin-clavulanate, and topical wound care after only a few days of treatment. Regarding the use and role of antibacterial therapy in this case, the initial presentation suggested a worsening cellulitis despite adequate coverage for typical gram-positive bacterial causes of cellulitis (Streptococcus pyogenes andStaphylococcus aureus) initially with clindamycin and then with linezolid to treat possible methicillin-resistantS. aureus (MRSA). Failure to respond to these first-line empiric agents suggested either inadequate spectrum of antimicrobial activity due to an atypical or polymicrobial infection, presence or development of antimicrobial resistance in the pathogen, or need for drainage of an abscess not penetrated by the antimicrobial agent. Clinical worsening in this immunocompromised host with possible environmental inoculation while carrying wood thus prompted modifying coverage and bedside debridement to avert the rare, but potentially life-threatening circumstance of PCC with superimposed bacterial infection [42]. Piperacillin/tazobactam was initiated to cover gram-negative bacteria includingPseudomonas aeruginosa and anaerobes, and linezolid was changed to vancomycin for possible ongoing MRSA and other gram-positive activity. Either gram-negative organisms or a resistantS. aureus (including rare cases of linezolid-resistantS. aureus) from the purulent drainage would have been isolated in culture or visualized on gram stain. Fastidious pathogens and anaerobes, though difficult to isolate in the laboratory, would typically occur in the context of polymicrobial infection, and even if not isolated, evidence of bacteria would be expected on gram stain. The complete absence of microbiologic data to support a bacterial process in this case suggests that the antibacterials did not play a role in the healing process.As this case illustrates, however, the overlapping manifestations between PCC and complicated bacterial skin and soft tissue infections may necessitate an early multidisciplinary approach involving infectious diseases and surgery consultants. Indeed, as our patient’s treatment was complicated by intolerance to liposomal amphotericin B and a potential superimposed bacterial infection, we cannot dismiss that early debridement facilitated more rapid clinical improvement. Although data supporting the role of surgical debridement in the management of PCC is lacking [43], the use of this strategy as an augmentation to systemic antifungal therapy may be a consideration for patients in whom early drug intolerance is noted, or concerns of potential hepatotoxicity, QTc prolongation, or drug-drug interactions resultant from long-term azole therapy are substantial. Similarly, topical Pluronic antimicrobial cream for postdebridement wound healing is commonly used in our facility [44, 45], but the literature guiding its specific use in PCC is lacking. While the nystatin contained in Pluronic could be active againstCryptococcus, it should be emphasized that treatment of any cryptococcal infection should include systemic therapy, and the role of post-debridement topical therapy in this case was to facilitate wound healing in a patient taking chronic corticosteroids rather than for any direct anti-cryptococcal effect.In summary, our case illustrates that prompt microbiologic testing and thorough evaluations for opportunistic atypical infections such as PCC should be considered in diabetic and immunocompromised patients who present with cellulitis that fails to respond to empiric antibiotic therapy. This case also demonstrates successful treatment of PCC with extended fluconazole monotherapy and local wound care. Clinicians should remain alert to the possibility of fungal skin soft tissue infections or coexistence of both bacterial and fungal infections. Although it is rare, coinfection ofC. neoformans with bacterial infection can be devastating, particularly in immunocompromised hosts, if the diagnosis is delayed [42]. Finally, this case serves as a reminder to educate immunosuppressed patients about occupational risks from environmental exposures including unprotected handling of pigeons, decaying wood, and soil.



---

*Source: 131356-2015-02-02.xml*